| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $109.2M | -35.5% |
| SG&A Expense | $47.2M | -20.0% |
| Operating Income | -$156.4M | +31.5% |
| Income Tax | $0 | — |
| Net Income | -$149.3M | +29.0% |
| EPS (Basic) | -$2.43 | +30.0% |
| EPS (Diluted) | -$2.43 | +30.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $45.4M | -36.2% |
| Short-term Investments | $145.5M | -48.9% |
| Current Assets | $196.4M | -45.8% |
| Total Assets | $225.2M | -43.3% |
| Current Liabilities | $16.4M | -50.7% |
| Long-term Debt | $0 | -100.0% |
| Total Liabilities | $44.0M | -52.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$128.3M | +17.5% |
| Capital Expenditures | $374K | -90.3% |
| Investing Cash Flow | $134.3M | -4.3% |
| Financing Cash Flow | -$31.7M | -237.1% |
| Free Cash Flow | -$128.7M | +19.2% |
| Stockholders' Equity |
| $181.2M |
| -40.4% |